论文部分内容阅读
目的:探讨VEGF和p53在肝癌组织中表达与肝癌预后的关系,为肝癌的防治提供新的思路。方法:回顾性分析了2006年1月到2009年8月收治的40例肝癌患者的临床资料,采用免疫组织化学法测定肝癌组织、癌旁组织和正常组织中VEGF和p53的表达。结果:VEGF和p53阳性表达率在肝癌组分别为62.5%和47.5%,癌旁组分别为22.5%和2.5%,在正常组未检测到VEGF和p53阳性表达,三组之间比较有显著性差异(P<0.05);本组40例肝癌患者术后均获随访,22例复发;复发组患者癌组织中VEGF和p53的阳性表达率均高于未复发组,相比较有显著性差异(P<0.05)。结论:在肝癌组织中存在VEGF和p53的异常表达,VEGF和p53异常表达与肝癌的预后密切相关。
Objective: To investigate the relationship between the expression of VEGF and p53 in hepatocellular carcinoma (HCC) and the prognosis of hepatocellular carcinoma (HCC), and to provide new ideas for the prevention and treatment of HCC. Methods: The clinical data of 40 patients with HCC who were treated from January 2006 to August 2009 were retrospectively analyzed. The expressions of VEGF and p53 were detected by immunohistochemistry in hepatocellular carcinoma tissues, adjacent tissues and normal tissues. Results: The positive expression rates of VEGF and p53 in hepatocellular carcinoma were 62.5% and 47.5% respectively, while those in paracancer tissues were 22.5% and 2.5% respectively. No positive expression of VEGF and p53 was detected in normal group, with significant difference between the three groups (P <0.05). Forty HCC patients were followed up and 22 patients relapsed after surgery. The positive rates of VEGF and p53 in recurrence group were significantly higher than those in non-recurrence group (P <0.05) P <0.05). Conclusion: Abnormal expression of VEGF and p53 exists in HCC tissues. The abnormal expression of VEGF and p53 is closely related to the prognosis of HCC.